MSN - AP World http://syn2.thecanadianpress.com:8080/mrss/feed/fcf7391a2f354311807f0501c16bde6a MSN - AP World Copyright © 2010-2018 The Canadian Press. All rights reserved. http://www.rssboard.org/rss-specification Mon, 24 Jan 2022 22:01:46 +0000 FDA panel reviews Pfizer's COVID vaccine for kids http://syn2.thecanadianpress.com:8080/mrss/feed/fcf7391a2f354311807f0501c16bde6a/cfe63b8eb90f4fdca76977251a5ce9f4 U.S. health advisers are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective for 5- to 11-year-olds. Tuesday's meeting of the FDA panel is the first step toward expanding vaccinations to 28 million youngsters. (Oct. 26) cfe63b8eb90f4fdca76977251a5ce9f4 Tue, 26 Oct 2021 14:08:37 +0000 SHOTLIST:RESTRICTION SUMMARY:++ONSCREEN GRAPHICS AT SOURCE++U.S. FOOD AND DRUG ADMINISTRATIONLocation unknown - 26 October 2021++EDIT STARTS ON SOUNDBITE++1. SOUNDBITE (English) Dr. Peter Marks, FDA vaccine chief:"We'll be considering the proposed amendment to the emergency use authorization of Pfizer-BioNTech COVID-19 vaccine for use in children ages 5 to 11 years of age. ++WHITE FLASH++2. SOUNDBITE (English) Dr. Doran Fink, FDA deputy director:"This request includes use of a lower mRNA content, 10 micrograms, than authorized for use in older age groups, 30 micrograms. That is, we are considering the use of an age-appropriate dose level because as we pediatricians are fond of saying, children are not simply small adults. ++WHITE FLASH++3. SOUNDBITE (English) Dr. Peter Marks, FDA vaccine chief:"Far from being spared from this harm of COVID-19 in the 5- to 11-year-old age range, there have been over 1.9 million infections, over 8,300 hospitalizations, about a third of which have required intensive care unit stays.++WHITE FLASH++4. SOUNDBITE (English) Dr. Peter Marks, FDA vaccine chief:"In addition, infections have caused many school closures and disrupted the education and socialization of children."++WHITE FLASH++5. SOUNDBITE (English) Dr. Peter Marks, FDA vaccine chief:"I want to acknowledge the fact that there are strong feelings that have clearly been expressed by members of the public, both for and against the use of the Pfizer-BioNTech vaccine under emergency use authorization for this age group of 5- to 11-year-old children. To be clear, today's discussion is going to be about the scientific data that are presented, and it's not about vaccine mandates which are left to other entities outside of FDA."++ENDS ON SOUNDBITE++STORYLINE:U.S. health advisers are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective for 5- to 11-year-olds. Tuesday's meeting of the Food and Drug Administration panel is the first step toward expanding vaccinations to 28 million young children.A study of elementary schoolchildren found the Pfizer shots are nearly 91% effective at preventing symptomatic infection, even though the youngsters received just a third of the dose given to teens and adults.In a preliminary analysis last week, Food and Drug Administration reviewers said that protection would "clearly outweigh" the risk of a very rare side effect in almost all scenarios of the pandemic. Now FDA's advisers are combing through that data to see if they agree.  If the FDA authorizes the kid-size doses, there's still another step: Next week, the Centers for Disease Control and Prevention will have to decide whether to recommend the shots and which youngsters should get them.While children are at lower risk of severe COVID-19 than older people, 5- to 11-year-olds still have faced substantial illness — including over 8,300 hospitalizations, about a third requiring intensive care, and nearly 100 deaths, FDA vaccine chief Dr. Peter Marks told the advisory panel.In addition, "infections have caused many school closures and disrupted the education and socialization of children," he said."I want to acknowledge the fact that there are strong feelings" among the public for and against child vaccinations, Marks added, noting that the discussion would be on scientific data "not about vaccine mandates, which are left to other entities outside of FDA."Full-strength shots made by Pfizer and its partner BioNTech already are recommended for everyone 12 and older, but pediatricians and many parents are clamoring for protection for even younger children. The extra-contagious delta variant has caused an alarming rise in pediatric infections — and families are frustrated with school quarantines and having to say no to sleepovers and other rites of childhood to keep the virus at bay.States are getting ready to roll out shots for little arms, in special orange-capped vials to distinguish them from adult vaccine, as soon as the government gives the OK. More than 25,000 pediatricians and other primary care providers have signed up so far to offer vaccination.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.===========================================================Clients are reminded: (i) to check the terms of their licence agreements for use of content outside news programming and that further advice and assistance can be obtained from the AP Archive on: Tel +44 (0) 20 7482 7482 Email: info@aparchive.com(ii) they should check with the applicable collecting society in their Territory regarding the clearance of any sound recording or performance included within the AP Television News service (iii) they have editorial responsibility for the use of all and any content included within the AP Television News service and for libel, privacy, compliance and third party rights applicable to their Territory. U.S. health advisers are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective for 5- to 11-year-olds. Tuesday's meeting of the FDA panel is the first step toward expanding vaccinations to 28 million youngsters. (Oct. 26) FDA panel reviews Pfizer's COVID vaccine for kids